同仁堂(600085.SH):2024年淨利潤同比下降8.54% 擬10派5元
格隆匯4月3日丨同仁堂(600085.SH)公佈2024年年度報吿,報吿期實現營業收入185.97億元,同比增長4.12%;歸屬於上市公司股東的淨利潤15.26億元,同比下降8.54%;基本每股收益1.113元。擬向全體股東每10股派發現金紅利5.00元(含税)。
公司主營業務為中成藥的生產與銷售,擁有包括中藥材種植、中藥材加工、中成藥研發、中成藥生產、醫藥物流配送、藥品批發和零售在內的完整產業鏈條。公司常年生產的中成藥超過400個品規,產品劑型豐富,覆蓋內科、外科、婦科、兒科等類別,以安宮牛黃丸、同仁牛黃清心丸、同仁大活絡丸、六味地黃丸,金匱腎氣丸為代表的產品以及眾多經典藥品家喻户曉,蜚聲海內外。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.